“VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN”, Int. J. Pharm. Sci. Drug Res., vol. 9, no. 5, pp. 224–227, Sep. 2017, doi: 10.25004/IJPSDR.2017.090504.